Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Leukaemias
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Leukaemias
    TopAbstracts in Leukemias 07/01/2009 - (DGNews)
    TopAbstracts in Leukemias 06/24/2009 - (DGNews)
    Incidence of Febrile Neutropenia After Chemotherapy in Hospitalised Patients Appears Lower Than Expected in Canada: Presented at ICC - (DGDispatch)
    TopAbstracts in Leukemias 06/17/2009 - (DGNews)
    Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials - (JAMA)

    News archive

     Recent webcasts/CME - Leukaemias
    • Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents
    • Interpreting New Findings on Epigenetic Changes in MDS and AML-What Impact Will They Have on Treatment?
    • Do Modified Treatment and Novel Therapies Augment Clinical Benefit in AML?
    • Crafting an Individualized Approach to MDS Therapy: New Data on Prognostic Models and Management of Higher Risk Disease
    • Bone Marrow Failure Syndromes Optimizing Outcomes Worldwide through Disease Understanding

      Webcasts/CME archive

       Recent cases - Leukaemias
        Chronic Neutrophilic Leukemia with Congenital Robertsonian Translocation Successfully Treated with Allogeneic Bone Marrow Transplantation in a Young Man
        Complete Remission of Primary Plasma Cell Leukemia with Bortezomib, Doxorubicin, and Dexamethasone: A Case Report
        An Unusual Presentation of Precursor T Cell Lymphoblastic Leukemia/Lymphoma with Cholestatic Jaundice: Case Report
        Gum Hypertrophy
        Cryptococcal Meningitis Presenting with Recurrent Syncope in a Patient with Chronic Lymphoid Leukemia: A Case Report

        Cases archive
          




        my personal edition > leukaemias > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Vion Pharmaceuticals Receives Orphan Drug Designation for Cloretazine (VNP40101M) in Europe for Treatment of Acute Myeloid Leukemia

        NEW HAVEN, CN -- January 23, 2006 -- Vion Pharmaceuticals, Inc. announced today that orphan designation was granted by the European Commission to its lead anticancer agent, Cloretazine® (VNP40101M), for the treatment of acute myeloid leukemia.

        The designation was granted to Vion (UK) Limited, the Company's wholly-owned European subsidiary and will appear on the European Medicines Agency website (www.emea.eu.int <http://www.emea.eu.int>) under the product name of 1,2-bis (methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl] hydrazine.

        Receipt of the designation followed from a favorable opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency. Opinions on orphan medicinal products designations are based on the following cumulative criteria: (i) the seriousness of the condition, (ii) the existence or not of alternative methods of diagnosis, prevention or treatment and (iii) the rarity of the condition (considered to affect not more than five in ten thousand persons in the European Community) and (iv) the presentation of evidence of medical plausibility.

        Acute myeloid leukemia (AML) is considered to affect about 32,000 persons in the European Union. Orphan drug status is granted by the European Commission to promote development of drugs to treat rare diseases or conditions. Orphan drug designation entitles Cloretazine® to: (i) ten years of market exclusivity for in the indication of AML; (ii) protocol assistance from the European Medicines Agency to optimize drug development in preparing a dossier that will meet regulatory requirements; (iii) reduced fees associated with applying for market approval; and (iv) access to European Union research funding.

        An orphan designation is not a marketing authorization. As a consequence, demonstration of quality, safety and efficacy will be necessary before Cloretazine® can be granted a marketing authorization.

        Vion Pharmaceuticals, Inc. is developing cancer therapeutics. Vion has two agents in clinical trials: Cloretazine®, a unique sulfonylhydrazine alkylating agent, is being evaluated in a phase 3 trial in combination with cytarabine in relapsed acute myelogenous leukemia.

        Trials of Cloretazine® as a single agent in previously untreated elderly acute myelogenous leukemia and high-risk myelodysplastic syndrome, adult and pediatric brain tumors, small cell lung cancer and chronic lymphocytic leukemia, and in combination with temozolomide in hematologic malignancies, are also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating KS119W, a hypoxia-selective compound from the sulfonylhydrazine class, and heterocyclic hydrazones. The Company also is seeking development partners for TAPET®, its modified Salmonella vector used to deliver anticancer agents directly to tumors.


        SOURCE: Vion Pharmaceuticals, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send